CancerDrs

Pancreatic Cancer clinical trials in Kansas

16 actively recruiting pancreatic cancer trials at 15 sites across Kansas.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …

Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in Kansas:
  • University of Kansas Cancer Center — Kansas City, Kansas
  • Lawrence Memorial Hospital — Lawrence, Kansas
  • The University of Kansas Cancer Center - Olathe — Olathe, Kansas
  • University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
  • Salina Regional Health Center — Salina, Kansas
Phase 2, Phase 3 Recruiting Industry

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in partici…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07076121
Sites in Kansas:
  • Local Institution - 0125 — Westwood, Kansas
Phase 2 Recruiting Network

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Kansas:
  • Central Care Cancer Center - Garden City — Garden City, Kansas
  • Central Care Cancer Center - Great Bend — Great Bend, Kansas
  • Mercy Hospital Pittsburg — Pittsburg, Kansas
Phase 2 Recruiting Academic/Other

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…

Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in Kansas:
  • Ohio State University Telemedicine — Colby, Kansas
  • Ohio State University-Telemedicine — Kansas City, Kansas
  • Ohio State University-Telemedicine — Wichita, Kansas
Phase 1, Phase 2 Recruiting NIH

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nod…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04172532
Sites in Kansas:
  • University of Kansas Clinical Research Center — Fairway, Kansas
  • HaysMed — Hays, Kansas
  • University of Kansas Cancer Center — Kansas City, Kansas
  • Lawrence Memorial Hospital — Lawrence, Kansas
  • The University of Kansas Cancer Center - Olathe — Olathe, Kansas
Phase 1, Phase 2 Recruiting Industry

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Kansas:
  • The University of Kansas Clinical Research Center — Westwood, Kansas
Phase 1, Phase 2 Recruiting Academic/Other

Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

Pancreatic cancer is a deadly disease and will be the second leading cause of cancer related death behind lung cancer by 2030. Over 62,000 people are diagnosed each year in the United States with about 90% succumbing to the disease within …

Sponsor: University of Kansas Medical Center
NCT ID: NCT06736717
Sites in Kansas:
  • The University of Kansas Cancer Center, Westwood Campus — Kansas City, Kansas
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Kansas:
  • The University of Kansas Cancer Center, Investigational Drug Services — Fairway, Kansas
  • The University of Kansas Clinical Research Center — Fairway, Kansas
  • The University of Kansas Hospital — Kansas City, Kansas
  • The University of Kansas Medical Center Medical Office Building — Kansas City, Kansas
  • University of Kansas Hospital Cambridge North Tower A — Kansas City, Kansas
Phase 1 Recruiting Industry

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT05365581
Sites in Kansas:
  • University of Kansas Cancer Center — Westwood, Kansas
Phase 1 Recruiting Industry

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as monotherapy…

Sponsor: BeiGene
NCT ID: NCT06585488
Sites in Kansas:
  • University of Kansas Medical Center Research Institute — Kansas City, Kansas
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Kansas:
  • Central Care Cancer Center - Garden City — Garden City, Kansas
  • Central Care Cancer Center - Great Bend — Great Bend, Kansas
  • Veteran Administration Eastern Kansas Healthcare — Leavenworth, Kansas
  • Mercy Hospital Pittsburg — Pittsburg, Kansas
  • Cotton O'Neil Cancer Center / Stormont Vail Health — Topeka, Kansas
Recruiting Academic/Other

Pancreatic Cancer Early Detection Consortium

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individ…

Sponsor: Arbor Research Collaborative for Health
NCT ID: NCT04970056
Sites in Kansas:
  • University of Kansas Medical Center — Kansas City, Kansas
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Kansas:
  • Saint Luke's Cancer Instititute - South — Overland Park, Kansas
Recruiting Industry

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…

Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Kansas:
  • Research Site — Topeka, Kansas

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25